User menu

The BLAST trial for MRD+ adult B-precursor acute lymphoblastic leukaemia (B-ALL) patients investigates a bi-specific anti-CD19/anti-CD3 BITE® antibody (blinatumomab®)

Bibliographic reference Graux, Carlos. The BLAST trial for MRD+ adult B-precursor acute lymphoblastic leukaemia (B-ALL) patients investigates a bi-specific anti-CD19/anti-CD3 BITE® antibody (blinatumomab®). In: Belgian Journal of Hematology, Vol. 3, no.4, p. 155-156 (2012)
Permanent URL http://hdl.handle.net/2078.1/147280